Applause! Lizhu has won the MSCI ESG Global AAA rating for consecutive years.
Published Time:
2024-08-02
Recently, the international authoritative index company MSCI (Morgan Stanley Capital International) announced the latest annual ESG (Environmental, Social and Governance) rating results for Lizhu. In 2024, Lizhu's MSCI ESG rating retained the highest global rating of AAA.
As of the date of this rating update, only 6 companies out of 250 companies in the global pharmaceutical industry received the highest AAA rating from MSCI ESG. Besides Lizhu, the other 5 are Merck (Germany), Novo Nordisk (Denmark), Zoetis (USA), Daiichi Sankyo (Japan), and Astellas Pharma (Japan). Lizhu is the first and only Chinese company in the global pharmaceutical industry to receive an MSCI AAA rating, and also the only pharmaceutical company in China to receive an MSCI AAA rating for two consecutive years.


In addition, Lizhu received an AA rating from Wind ESG in June this year, marking its third consecutive year with an AA rating. The Wind ESG comprehensive score is composed of management practices and controversial events. The rating framework aligns with the international mainstream ESG system architecture while fully considering the current situation of the Chinese capital market, regulatory policies, and the specific ESG practices of Chinese companies. Currently, the Wind ESG rating covers all A-share and H-share listed companies and important bond issuers, approximately 10,000+.

Lizhu has always selectively and phased implemented improvement actions, targeting the characteristics of the pharmaceutical industry and combining its own actual situation. In terms of governance, Lizhu has always attached great importance to ESG management, establishing an ESG governance structure with the board of directors as the highest decision-making body. ESG assessment indicators are included in the personal performance appraisal of ESG working group members, and a compensation mechanism linked to sustainable development has been established. Environmentally, Lizhu actively implements the green and low-carbon operation concept, adopts energy-saving and emission-reduction measures, and steadily advances towards the goal of carbon neutrality by 2055. Socially, Lizhu always adheres to the people-oriented approach, allowing employees to grow in an equal, respectful, inclusive, and diverse work environment; actively carrying out public welfare activities such as chronic disease prevention and control and rural revitalization, practicing corporate social responsibility. Lizhu upholds the mission of "patient life quality first", taking the promotion of inclusive health and public health as the original intention of corporate operations, continuously paying attention to unmet clinical needs, steadily promoting product innovation, improving product accessibility and affordability, and benefiting more people worldwide with high-quality products.
Through continuous ESG governance improvements, Lizhu has received widespread recognition and affirmation from society and rating agencies. In addition to the continuous and rapid improvement of MSCI ESG and Wind ESG ratings, Lizhu was also selected this year for S&P Global's Sustainability Yearbook 2024 and Sustainability Yearbook 2024 (China Edition), and received S&P's 2023 "Industry Best Progress Company" award, the only one in the global pharmaceutical industry, and the only one in the Chinese pharmaceutical industry.
About MSCI ESG
MSCI is an international company that provides global indexes and related derivative financial products. As the benchmark index most widely used by global portfolio managers, its ESG rating results are an important basis for decision-making by major global investment institutions. Currently, MSCI ESG ratings cover 8,500 companies and over 680,000 global equities and fixed-income securities (as of June 2020). It mainly refers to the company's ESG reports, official websites, news reports, and other publicly available information to evaluate the company's sustainable development performance from an ESG perspective, assessing the ESG risks faced by the company, the potential opportunities of its core business, and ESG issues of general concern to the industry.
About Wind ESG
The Wind ESG rating is based on the core connotation of ESG, aligning with international standards and evaluation frameworks. Based on the characteristics of Chinese enterprise development and the current situation of the capital market, it uses a scientific and rigorous methodology to predictively evaluate the company's material ESG risks and its ability to operate sustainably. Wind ESG rates companies from AAA to CCC based on the ESG risks and opportunities inherent in the company's industry and its performance relative to its peers. The ESG rating is updated annually or with major events.